Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AngioDynamics, Inc. - Common Stock (NQ: ANGO )

12.94 +3.54 (+37.66%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AngioDynamics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
AngioDynamics' Q4 Top-Line Beats Street View, Issues Mixed FY23 Guidance
Via Benzinga
Recap: AngioDynamics Q4 Earnings
  AngioDynamics (NASDAQ:ANGO) reported its Q4 earnings results on Tuesday, July 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings AngioDynamics reported in-line... 
Via Benzinga
AngioDynamics Reports Fiscal Year 2022 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Year 2023 Guidance
From AngioDynamics, Inc.
Via Business Wire
U.S. Stock Futures Down Ahead Of PepsiCo Earnings
Pre-open movers 
Via Benzinga
Earnings Scheduled For July 12, 2022
Companies Reporting Before The Bell • AngioDynamics (NASDAQ:ANGO) is estimated to report quarterly earnings at $0.01 per share on revenue of $83.25 million. 
Via Benzinga
AngioDynamics Posts Wider Q3 Loss On Higher Costs, Reaffirms FY22 Outlook
Via Benzinga
PepsiCo, GameStop And 3 Stocks To Watch Heading Into Tuesday
With the US stock futures trading lower this morning on Tuesday after the Nasdaq recorded sharp losses in the previous session, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Earnings Preview: AngioDynamics
AngioDynamics (NASDAQ:ANGO) is set to give its latest quarterly earnings report on Tuesday, 2022-07-12. Here's what investors need to know before the announcement. Analysts estimate that AngioDynamics... 
Via Benzinga
AngioDynamics to Report Fiscal 2022 Fourth Quarter and Full-Year Financial Results on July 12, 2022
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Present at the UBS Global Healthcare Conference
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Present at the BofA Securities Healthcare Conference
From AngioDynamics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers IMAC Holdings (NASDAQ:IMAC) shares increased by 60.0% to $1.6 during Thursday's pre-market session. The market value of their outstanding shares is at $41.9 million. 
Via Benzinga
The Daily Biotech Pulse: Pfizer Goes Shopping, AstraZeneca Inks Bispecific Antibody Deal, Aptinyx Faces Clinical Study Setback, Erytech Jumps On Data And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
AngioDynamics Reports Fiscal 2022 Third Quarter Financial Results; Reaffirms Fiscal Year 2022 Guidance
From AngioDynamics, Inc.
Via Business Wire
Earnings Scheduled For April 7, 2022
Companies Reporting Before The Bell • Cazoo Gr (NYSE:CZOO) is likely to report earnings for its fourth quarter. 
Via Benzinga
AngioDynamics's Earnings: A Preview
AngioDynamics (NASDAQ:ANGO) is set to give its latest quarterly earnings report on Thursday, 2022-04-07. Here's what investors need to know before the announcement. Analysts estimate that AngioDynamics... 
Via Benzinga
AngioDynamics's Earnings Outlook
AngioDynamics (NASDAQ:ANGO) is set to give its latest quarterly earnings report on Thursday, 2022-04-07. Here's what investors need to know before the announcement. Analysts estimate that AngioDynamics... 
Via Benzinga
A Preview Of AngioDynamics's Earnings
AngioDynamics (NASDAQ:ANGO) is set to give its latest quarterly earnings report on Thursday, 2022-04-07. Here's what investors need to know before the announcement. Analysts estimate that AngioDynamics... 
Via Benzinga
AngioDynamics to Present at the Needham Virtual Healthcare Conference
From AngioDynamics, Inc.
Via Business Wire
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that... 
Via Benzinga
AngioDynamics to Report Fiscal 2022 Third Quarter Financial Results on April 7, 2022
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From AngioDynamics, Inc.
Via Business Wire
4 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t... 
Via Benzinga
AngioDynamics Earnings Perspective: Return On Capital Employed
According to Benzinga Pro data, during Q1, AngioDynamics (NASDAQ:ANGO) posted sales of $76.97 million. Earnings were up 64.19%, but AngioDynamics still reported an overall loss of... 
Via Benzinga
AngioDynamics Reports Fiscal 2022 Second Quarter Financial Results; Reaffirms Revenue Guidance; Revises Gross Margin and Adjusted EPS Guidance
From AngioDynamics, Inc.
Via Business Wire
Earnings Scheduled For January 6, 2022
Companies Reporting Before The Bell • Northern Technologies (NASDAQ:NTIC) is estimated to report quarterly earnings at $0.18 per share on revenue of $16.90 million.... 
Via Benzinga
AngioDynamics to Present at the Needham Virtual Growth Conference
From AngioDynamics, Inc.
Via Business Wire
The Week Ahead In Biotech (Jan. 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week
Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. Here are the key catalysts that can sway biotech stocks in the unfolding week. 
Via Talk Markets
AngioDynamics to Report Fiscal 2022 Second Quarter Financial Results on January 6, 2022
From AngioDynamics, Inc.
Via Business Wire
Is This Under-the-Radar Medical Devices Stock a Buy?
The medical devices company beat analyst expectations in the first quarter of its new fiscal year. Could it be a buy? 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.